Overview
Vivien Mak practices practicing medicine in Sar, China.
Their clinical expertise encompasses Febrile Neutropenia, Acute Promyelocytic Leukemia, Alpha Thalassemia, and Acute Myeloid Leukemia (AML).
They are actively involved in clinical research, co-authoring 9 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Vivien M. Mak
Is Vivien M. Mak a top-rated expert for Febrile Neutropenia?
MediFind is an objective health platform that identifies experts based on real-world data. Vivien M. Mak is classified as an Experienced expert for Febrile Neutropenia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Vivien M. Mak participate in research or clinical trials?
Yes. Vivien M. Mak has published 9 articles and abstracts on conditions like Febrile Neutropenia. You can view a list of Vivien M. Mak's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Acute Myeloid Leukemia (AML)
- Acute Promyelocytic Leukemia
- Alpha ThalassemiaMak isExperienced. Learn about Alpha Thalassemia.
- Febrile NeutropeniaMak isExperienced. Learn about Febrile Neutropenia.
- LeukemiaMak isExperienced. Learn about Leukemia.